Cesamet (nabilone) is a synthetic analogue of THC, the active ingredient in marijuana. It is similar in chemical structure to dronabinol.
Cesamet is taken orally as a pill and enters the bloodstream through the linings of the stomach.
Cesamet was originally developed by Eli Lilly and Company, which discontinued the drug in 1989. It was bought by Valeant Pharmaceuticals in 2004.
Cesamet was first approved by the FDA in 1985 but was not available in the U.S. until 2006.
1985 – Received FDA approval for treating nausea and vomiting in chemotherapy patients
1989 – Withdrawn from U.S. market
2006 – Re-approved by FDA